Quoin Pharmaceuticals (NASDAQ:QNRX) Director Anthony James Culverwell Acquires 6,146 Shares of Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Director Anthony James Culverwell bought 6,146 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were acquired at an average cost of $4.88 per share, for a total transaction of $29,992.48. Following the purchase, the director directly owned 40,364 shares in the company, valued at $196,976.32. This trade represents a 17.96% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Quoin Pharmaceuticals Stock Performance

Shares of NASDAQ:QNRX opened at $6.51 on Wednesday. The firm has a market cap of $13.09 million, a price-to-earnings ratio of -0.26 and a beta of 1.50. The firm has a fifty day moving average price of $4.77 and a 200 day moving average price of $5.89. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a fifty-two week low of $3.25 and a fifty-two week high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29). As a group, research analysts predict that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 earnings per share for the current year.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Simplify Asset Management Inc. bought a new stake in Quoin Pharmaceuticals in the fourth quarter worth $252,000. ADAR1 Capital Management LLC purchased a new stake in shares of Quoin Pharmaceuticals in the fourth quarter valued at $840,000. Boothbay Fund Management LLC purchased a new stake in shares of Quoin Pharmaceuticals in the fourth quarter valued at $863,000. SummitTX Capital L.P. bought a new stake in shares of Quoin Pharmaceuticals in the 4th quarter worth about $935,000. Finally, Millennium Management LLC purchased a new position in shares of Quoin Pharmaceuticals during the 4th quarter worth about $1,080,000. Institutional investors own 8.63% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on QNRX shares. ThinkEquity assumed coverage on Quoin Pharmaceuticals in a research note on Monday, June 15th. They set a “buy” rating for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, July 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.